EHT Technologies GmbH was founded in 2015 based upon decades of research on cardiac tissue engineering conducted by Professor Thomas Eschenhagen, M.D. at the University Medical Center Hamburg-Eppendorf. Cardiomyocytes derived from human induced pluripotent stem cells (hiPSC) are an innovative research technology for cardiac drug development programs. Engineered heart tissues are three-dimensional, hydrogel-based muscle constructs that are cultivated under mechanical load and that mimic the physiological conditions of the heart in a dish.
In January 2021, EHT Technologies was acquired by DiNAQOR, a gene therapy company developing next generation AAV therapies to transform the lives of patients with rare genetic diseases. DiNAQOR’s engineered heart tissue division is led by Dr. Ingra Mannhardt, Head of System Development and Dr. Alexandra Rhoden, Head of Assay Development.